Hormone Refractory Prostate Cancer Market By Treatment Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery) By Application (Hospitals, Specialty Clinics , Ambulatory Surgical Centers) By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Feb 2024
Report ID: 47603
Number of Pages: 375
Format:

Fact Checked

Cite this Research

- 1. Hormone Refractory Prostate Cancer Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Hormone Refractory Prostate Cancer Market Overview
  - 3.1. Hormone Refractory Prostate Cancer Market Dynamics
    
    3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Production Analysis by Region/Company
  - 3.9. Industry chain Analysis
  - 3.10. Marketing Strategy
- 4. Global Hormone Refractory Prostate Cancer Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Hormone Refractory Prostate Cancer Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Chemotherapy
  - 4.4. Hormonal Therapy
  - 4.5. Immunotherapy
  - 4.6. Radiation Therapy
  - 4.7. Surgery
- 5. Global Hormone Refractory Prostate Cancer Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Hormone Refractory Prostate Cancer Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Hospitals
  - 5.4. Ambulatory Surgical Centers
  - 5.5. Specialty Clinics
- 6. Global Hormone Refractory Prostate Cancer Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    
    6.1.1. North America Hormone Refractory Prostate Cancer Market: Regional Trend Analysis
    
    6.1.1.1. US
    
    6.1.1.2. Canada
    
    6.1.1.3. Mexico
  - 6.2.1. Europe
    
    6.2.1. Europe Hormone Refractory Prostate Cancer Market: Regional Trend Analysis
    
    6.2.1.1. Germany
    
    6.2.1.2. France
    
    6.2.1.3. UK
    
    6.2.1.4. Russia
    
    6.2.1.5. Italy
    
    6.2.1.6. Spain
    
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    
    6.3.1. Asia-Pacific Hormone Refractory Prostate Cancer Market: Regional Trend Analysis
    
    6.3.1.1. China
    
    6.3.1.2. Japan
    
    6.3.1.3. Korea
    
    6.3.1.4. India
    
    6.3.1.5. Rest of Asia-Pacific
  - 6.4. Latin America
    
    6.4.1. Latin America Hormone Refractory Prostate Cancer Market: Regional Trend Analysis
    
    6.4.1.1. Brazil
    
    6.4.1.2. Argentina
    
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    
    6.5.1. Middle East and Africa Hormone Refractory Prostate Cancer Market: Regional Trend Analysis
    
    6.5.1.1. GCC
    
    6.5.1.2. South Africa
    
    6.5.1.3. Israel
    
    6.5.1.4. Rest of MEA
- 7. Global Hormone Refractory Prostate Cancer Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Astellas Inc
    
    7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
  - 7.4. Sanofi S.A
    
    7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
  - 7.5. Dendreon Corporation, Bayer AG
    
    7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
  - 7.6. Johnson & Johnson
    
    7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Astellas Pharma Inc
- AstraZeneca plc
- Johnson & Johnson
- Sanofi S.A.
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Merck & Co.
- Eli Lilly and Company
- Takeda Pharmaceuticals